Fast Facts: Myelodysplastic Syndromes

M.L. Arellano, P. Dyer

Description

Myelodysplastic syndromes (MDS) are a group of clonal myeloid blood disorders that affect older people. As the global population ages, the incidence of these disorders is increasing. As such, healthcare professionals need to be aware of MDS as a possible diagnosis and know how to identify those patients whose condition is most likely to transform to acute myeloid leukemia (AML). Fast Facts: Myelodysplastic Syndromes explains how these disorders are classified, how they present and how prognosis and the risk of transformation to AML are assessed. It also outlines the most appropriate management options for patients of different ages, together with an overview of the latest research under way to further understand MDS and how to treat it. This highly readable resource is the ideal primer on MDS for all members of the multidisciplinary team involved in the care of patients with MDS, including hematologists, hematology trainees, clinical nurse specialists and primary care providers. Table of Contents: • Epidemiology and etiology • Pathogenesis and presentation • Diagnosis and classification • Management • Supporting patients with MDS

Informations

• Publié par: S. Karger AG
• Date de parution: 12 février 2021
• Nombre de lectures: 0
• EAN13: 9783318068733
• Langue: English
• Poids de l'ouvrage: 3 Mo

Extrait

Fast Facts: Myelodysplastic Syndromes
First published 2021
Text 2021 Peter Dyer, Martha L Arellano
2021 in this edition S. Karger Publishers Ltd
S. Karger Publishers Ltd, Elizabeth House, Queen Street, Abingdon,
Oxford OX14 3LN, UK; Tel: [phone]
Book orders can be placed by telephone or email, or via the website.
Please telephone [phone] or email [e-mail]
To order via the website, please go to karger.com
Fast Facts is a trademark of S. Karger Publishers Ltd.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the express permission of the publisher.
The rights of Peter Dyer and Martha L Arellano to be identified as the authors of this work have been asserted in accordance with the Copyright, Designs Patents Act 1988 Sections 77 and 78.
The publisher and the authors have made every effort to ensure the accuracy of this book, but cannot accept responsibility for any errors or omissions.
For all drugs, please consult the product labeling approved in your country for prescribing information.
Registered names, trademarks, etc. used in this book, even when not marked as such, are not to be considered unprotected by law.
A CIP record for this title is available from the British Library.
ISBN 978-3-318-06872-6
Dyer P (Peter)
Fast Facts: Myelodysplastic Syndromes/Peter Dyer, Martha L Arellano
Cover image shows dysplastic changes in erythroid cells and immature/dysplastic forms of myeloid cells in a bone marrow sample from a patient with a myelodysplastic syndrome.
Typesetting by Amnet, Chennai, India.
Printed in the UK with Xpedient Print.
Made possible by a contribution from Takeda Pharmaceuticals Company Limited. Takeda did not have any influence on the content and all items were subject to independent peer and editorial review.
Contents
List of abbreviations
Introduction
Epidemiology and etiology
Pathogenesis and presentation
Diagnosis and classification
Management
Supporting patients with MDS
Useful resources
Index
List of abbreviations
AML: acute myeloid leukemia
ATG: antithymocyte globulin
AUC: area under the curve
CHIP: clonal hematopoiesis of indeterminate potential
CI: confidence interval
CMML: chronic myelomonocytic leukemia
CR: complete remission
DNA: deoxyribonucleic acid
ESA: erythropoiesis-stimulating agent
FDA: Food and Drug Administration
FISH: fluorescence in situ hybridization
GvHD: graft versus host disease
HI: hematologic improvement
HIV: human immunodeficiency virus
HLA-DR: human leukocyte antigen-DR isotype
HMA: hypomethylating agent
HR-MDS: high-risk MDS
HSC: hematopoietic stem cell
HSCT: hematopoietic stem cell transplantation
IPSS: International Prognostic Scoring System
IR-MDS: intermediate-risk MDS
IST: immunosuppressive therapy
LR-MDS: low-risk MDS
MDS: myelodysplastic syndromes
MDS-EB: MDS with excess blasts
MDS-MLD: MDS with multilineage dysplasia
MDS-RS: MDS with ring sideroblasts
MDS-SLD: MDS with single-lineage dysplasia
NGS: next-generation sequencing
OS: overall survival
PNH: paroxysmal nocturnal hemoglobinuria
RBC: red blood cell
RBC-TI: red blood cell-transfusion independence
RIC allo: reduced-intensity conditioning allogeneic HSCT
RIPSS: Revised International Prognostic Scoring System
RNA: ribonucleic acid
RS: ring sideroblast
SNP: single nucleotide polymorphism
t-AML: treatment-related AML
t-MDS: therapy-related MDS
WHO: World Health Organization
WPSS: WHO Classification-Based Prognostic Scoring System
Introduction
Myelodysplastic syndromes (MDS) are a heterogeneous group of closely related clonal hematopoietic myeloid disorders that affect older adults. The name is derived from the Greek words or myelos meaning marrow, and or dysplasia meaning abnormal morphology. MDS are characterized by ineffective hematopoiesis leading to cytopenias and their attendant complications (infection, bleeding and symptomatic anemia), and variable risk of transformation to acute myeloid leukemia (AML). The heterogeneity of MDS relates not only to differences in the morphological appearances of cells, but also to diversity in molecular and cytogenetic abnormalities detectable in the blood and marrow of patients with MDS.
Diagnosis of MDS must be distinguished from that of dysplasia associated with marrow failure syndromes and other clonal disorders, as well as non-clonal, non-malignant causes such as infections, nutritional deficiencies and intoxications. Accurate diagnosis requires excellent morphological evaluation, as well as cytogenetic and molecular data, in the context of peripheral blood cytopenias. Clinical correlation is also important to rule out familial syndromes and non-neoplastic causes of dysplasia.
MDS can be indolent non-progressive disorders, but they can also have an aggressive clinical course with (at times rapid) progression to AML in approximately 15-30% of patients. Various prognostic scoring systems may be used to predict clinical course and time to AML progression, and thus tailor therapy.
The overall 5-year probability of survival for patients with MDS remains poor at approximately 30%. Despite recent improvements in therapies and support, and although several targeted therapies are under investigation, current treatment options remain limited and allogeneic hematopoietic stem cell transplantation is the only potentially curative option for fit young patients with MDS.
This book is designed to provide hematology/oncology nurses, physicians and trainees with concise up-to-date guidance for accurate diagnosis, risk stratification and management of patients with MDS.
1 Epidemiology and etiology
Epidemiology
Myelodysplastic syndromes (MDS) predominantly affect older adults (median age of 71-76 years at the time of diagnosis) and affect men more commonly than women. The incidence of MDS increased in 2001-2003 and 2013-2017 from 3.3 to 4.9 per 100 000 persons per year ( Figure 1.1 ). 1 While the rising incidence may be attributed to increased awareness of the disease and improved diagnostic methods, we must not ignore the contribution of an aging population and the number of patients with therapy-related MDS (t-MDS). Figure 1.2 shows the marked increase in patients with MDS after age 70, reaching 54.2 cases per 100 000 in those aged 80 years and over. 1
Although the prevalence of MDS is difficult to estimate because of limitations in tracking, by both registry- and claims-based methods, it is estimated that 87 000 cases are diagnosed globally each year. Approximately 60 000-170 000 people are estimated to be living with MDS in the USA, with 10 000-15 000 new cases diagnosed annually. The European prevalence is estimated to be similar; the European incidence is around four cases per 100 000 persons per year (reaching 40-50 per 100 000 in patients aged 70 years). 2 , 3

Figure 1.1 Incidence of MDS in the USA by sex (persons per 100 000 per year) in 21 SEER areas (not all US territories represented). Surveillance, Epidemiology, and End Results. 1

Figure 1.2 Incidence of MDS by age and sex. Graph created from SEER data. 1
Etiology
Risk factors include age, male sex, prior radiation therapy and/or chemotherapy, exposure to organic solvents such as benzene, smoking and obesity. However, the vast majority (80%) of cases are idiopathic in nature (de novo MDS).
Previous exposure to chemotherapy and/or radiation is noted in 10-15% of patients (t-MDS or treatment-related acute myeloid leukemia [t-AML]). Time to development depends on the type and dose of exposure.
Alkylating agents , such as cyclophosphamide, chlorambucil, nitrosoureas, mechlorethamine and melphalan, have a latency of 6-7 years. 4
Topoisomerase-II inhibitors , such as etoposide and doxorubicin, have shorter latency ( 2 years), and more frequently present with t-AML. Accelerated transition from t-MDS to t-AML has been postulated in patients treated with topoisomerase-II inhibitors. 5
Mutational patterns of patients with t-MDS differ from those with de novo MDS, with a higher frequency of complex karyotype and p53 mutations. 6 Interestingly, the genetic features and clinical behaviors of MDS diagnosed in patients previously treated with radiation therapy alone differ from those in patients previously exposed to a combination of radiation and chemotherapy. The former tend to have more favorable cytogenetic lesions, lower-risk International Prognostic Scoring System (IPSS) scores and outcomes more similar to de novo MDS, while the latter have more adverse risk cytogenetics, higher-risk IPSS scores and inferior survival when compared with patients with de novo MDS. 7
Benzene is a known carcinogen associated with chromosomal strand breaks, epigenetic abnormalities and genomic instability, even at very low exposures. Cigarette smoke is known to contain benzene and several studies have suggested an increased risk of MDS and AML in cigarette smokers. A meta-analysis that included 25 studies revealed an odds ratio of 1.48 (95% confidence interval [CI] 1.17, 1.86; p = 0.001) for development of MDS among smokers, with a dose-response relationship. 8
Obesity. The prospective Million Women Study included a cohort of 1.3 million middle-aged UK women recruited between 1996 and 2001, followed them for 10 years on average and